Naslov
Moclobemide in treating patients with post-traumatic stress disorder

Autori
Folnegović-Šmalc, Vera ; Gošev, Miro ; Mimica, Ninoslav ; Makarić, Gordan ; Folnegović, Zdenko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
European Neuropsychopharmacology 4 (3 - special issue) - Abstracts of the VIIth Congress of the European College of Neuropsychopharmacology / - Amsterdam : Elsevier, 1994, 344-345

Skup
VIIth Congress of the European College of Neuropsychopharmacology

Mjesto i datum
Jeruzalem, Izrael, 16.10.1994. - 21.10.1994

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
post-traumatic stress disorder; moclobemide

Sažetak
The study included refugees and displaced people with diagnoses of post-traumatic stress disorder (PTSD), according to DSM-IIIR criteria. They were settled into camps for refugees and displaced persons during 1993. In this study there were 155 patients of both sexes, aged 18-55 years. The patients were on monotherapy, that is they were administered doses of moclobemide (Aurorix, Hoffman-La Roche), ranging from 100 to 300 mg/daily, depending on the efficacy and patient's tolerance of the drug. Only in a few cases a hypnotic was sporadically administered in evening therapy. The treatment period asted for a minimum of 3 months. The PTSD Interview (DSM-IIIR version) was applied at baseline. After every 2 weeks the patients were evaluated by the following scales: Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale, Clinical Global Impression, Adverse Event Report Form. At the end, the patient's subjective assessment of change in psychic condition was registered. If there was a key family member, his or her subjective assessment of the change in the patient's psychic state was also noted. Table 1. The assessment of psychic condition after 2 weeks and after 12 weeks of treatment with moclobemide in patients with PTSD Patients who after 2 weeks of treatment with moclobemide were evaluated as 'unchanged' or 'deteriorated' were excluded from the further follow-up. In 17 patients (10.9%) side-effects were expressed, with two side-effects present in three patients. The side-effects were as follows: dry mouth in 12 patients, akathisia in two cases, constipation in three and nausea in three cases. In conclusion, moclobemide proved a highly effective therapeutic agent in refugees and displaced people, that is in persons who continued to live in stressful conditions, and were diagnosed as PTSD. Side-effects were observed in 10.9% of the patients receiving moclobemide, and were no reason for discontinuation of therapy. As improvement was noted in the majority of patients, which was present already after 2 weeks of therapy, it is concluded that moclobemide is an effective drug, and is indicated in persons with PTSD.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA